Condition (MeSH)
Synovitis, Pigmented Villonodular
ClinicalTrials.gov lists 20 trials for Synovitis, Pigmented Villonodular or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Synovitis, Pigmented Villonodular itself; the rest are tagged with a narrower condition beneath it.
When did Synovitis, Pigmented Villonodular trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 4 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 2 |
| 2012 | 2 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 20 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Synovitis, Pigmented Villonodular trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 8 |
| Phase 3 | 4 |
| Not applicable | 1 |
| Observational | 3 |
How many Synovitis, Pigmented Villonodular trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Active, not recruiting | 4 |
| Completed | 12 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Synovitis, Pigmented Villonodular trials? (9)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AmMax Bio, Inc. | 3 |
| Daiichi Sankyo | 3 |
| Deciphera Pharmaceuticals, LLC | 2 |
| Abbisko Therapeutics Co, Ltd | 1 |
| Daiichi Sankyo Co., Ltd. | 1 |
Showing 5 of 9 sponsors.
Which drugs are being tested for Synovitis, Pigmented Villonodular? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pexidartinib | 3 |
| Pimicotinib | 2 |
| Vimseltinib | 2 |
| Cabiralizumab | 1 |
| Emactuzumab | 1 |
Showing 5 of 7 drugs.
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| AMB-05X | 3 |
| Nilotinib Pill | 2 |
| D. Midazolam | 1 |
| PLX73086 | 1 |
| Synovial biopsy | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Synovitis, Pigmented Villonodular trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 4 | 2 |
| Cellulitis | 4 | 1 |
| Migraine | 4 | 2 |
| Blood bilirubin increased | 3 | 1 |
| Hepatic enzyme abnormal | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Synovitis, Pigmented Villonodular? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: A case report. | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association | 2024 | Yes |
| Treatment updates on tenosynovial giant cell tumor. | Current opinion in oncology | 2022 | Yes |
| Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT. | European journal of cancer (Oxford, England : 1990) | 2022 | Yes |
| ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). | Future oncology (London, England) | 2020 | Yes |
| Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. | European journal of cancer (Oxford, England : 1990) | 2020 | Yes |
Showing 5 of 12 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Tenosynovial giant cell tumor | Point prevalence | 1-5 / 10 000 | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.